MANIPAL HEALTH ENTERPRI L Valuation
MANIPALHOS · Healthcare · Current price ₹760.6
Is MANIPAL HEALTH ENTERPRI L undervalued?
We estimate the fair value of MANIPAL HEALTH ENTERPRI L at ₹578 per share, against a market price of ₹717. That puts the share price about -19.4% above our estimate, at medium confidence. This is our view of what the business is worth, not a target price or a forecast of where the share price will go.
How this fair value is calculated
This estimate comes from 1 method: Fair multiple (P/E) (₹578). Each is weighted by how well its inputs held up for this company. The full working, including the assumptions and what data was missing, is set out below.
The range around this estimate
Our estimate for MANIPAL HEALTH ENTERPRI L spans ₹520 to ₹636. A margin of safety means buying meaningfully below the estimate: the wider the range, the more room the assumptions leave for error.
Valuation multiples
MANIPAL HEALTH ENTERPRI L trades at a P/E of 209.0x and a P/B of 5.9x, with a dividend yield of 0.0%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.
How we got this fair value
Every number below is part of the same estimate for MANIPAL HEALTH ENTERPRI L. Nothing here is a target price or a forecast of where the share price will go.
Workable, with real gaps. Weigh it alongside your own view rather than on its own.
Estimate range ₹520 – ₹636
Why this method for this business
The relative P/E and EV/EBITDA models are most appropriate for a hospital operator with a durable moat and stable cash flows. These models align with the asset-light, earnings-driven nature of the healthcare sector.
The models behind the number
Each method is weighted by how well its inputs held up for this company.
required inputs missing
- dcf: Not suitable for a hospital operator with high capital intensity and uncertain cash flows
- fair multiple (P/E): Already included in relative PE model
What was missing
- Lack of historical P/E data for the company
- Limited analyst coverage and dispersion in earnings estimates
What drives it
14 inputs, grouped by how strong each claim is
- Sector-median P/E
- 58.42×
- Peers used
- 6
- EPS (TTM)
- 7.71 ₹/share
peer-median
peer-median
computed
- Term: quality
- -0.3%
- Term: growth
- +40.0%
- Term: capital_allocation
- -1.4%
- Term: financial_strength
- +5.2%
- Term: history
- +0.0%
- Term: sector_rerating
- +0.0%
- Term: rate_regime
- +1.2%
- Term: risk
- +0.0%
quality 54/100 (about average) → neutral
durable ~59% CAGR (ROCE 12% > hurdle) → premium
capital allocation: steady → neutral
financial strength: low leverage (D/E 0.5) → mild premium
history: no reliable own-history P/E → not used
sector re-rating: no sector-norm history → not used
rates: risk-free 6.9% below ~7.1% normal → higher multiple
risk: no analyst-dispersion signal available → neutral (lowers confidence, not PE)
- Premium vs sector
- +28.4%
- Fair-multiple confidence
- 56%
- Fair P/E
- 75×
fundamentals + macro (not capped at own history)
data completeness + term agreement
sector median × ∏(1+term) — Dynamic Fair Multiple
Who computed this
A language model (qwen3:8b) selects the valuation method and the judgement inputs for MANIPAL HEALTH ENTERPRI L: which models suit the business, the moat, the growth and margin assumptions. It does not produce the number. The fair value itself is computed in Python by a deterministic engine (version 2026.08.1) from those inputs, so the same inputs always give the same result and every figure above can be traced to a source.
Estimated 14 Sept 2026. Re-run as new financials and news arrive.
How we value stocks
We estimate what a business is worth from its own economics: cash flows, returns on capital, and a multiple justified by its quality, rather than from where the share price has been. A fair value estimate is a view, not a verdict, and it is only as good as the inputs listed above.
Read the full fair-value methodologyUnderstand the ratios
More on MANIPAL HEALTH ENTERPRI L
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.